108 related articles for article (PubMed ID: 27444222)
21. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
22. Deal watch: AstraZeneca bets on FibroGen's anaemia drug.
Flight MH
Nat Rev Drug Discov; 2013 Oct; 12(10):730. PubMed ID: 24080688
[No Abstract] [Full Text] [Related]
23. Activation of purinergic receptor subtypes modulates odor sensitivity.
Hegg CC; Greenwood D; Huang W; Han P; Lucero MT
J Neurosci; 2003 Sep; 23(23):8291-301. PubMed ID: 12967991
[TBL] [Abstract][Full Text] [Related]
24. Deal watch: Trends in discovery externalization.
Mayhew S
Nat Rev Drug Discov; 2010 Mar; 9(3):183. PubMed ID: 20190781
[No Abstract] [Full Text] [Related]
25. Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs.
Flemming A
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743968
[No Abstract] [Full Text] [Related]
26. Deal watch: co-promotion deals: panacea or poison pill?
Borshell N; Papp T
Nat Rev Drug Discov; 2010 Nov; 9(11):831. PubMed ID: 21030991
[No Abstract] [Full Text] [Related]
27. Market watch: Upcoming market catalysts in Q2 2013.
Nguyen K
Nat Rev Drug Discov; 2013 Apr; 12(4):254. PubMed ID: 23535926
[No Abstract] [Full Text] [Related]
28. Deal watch: is deal-making becoming more difficult?
Borshell N
Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629282
[No Abstract] [Full Text] [Related]
29. Inhibition of Ca2+ signaling and glucagon secretion in mouse pancreatic alpha-cells by extracellular ATP and purinergic receptors.
Tudurí E; Filiputti E; Carneiro EM; Quesada I
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E952-60. PubMed ID: 18349114
[TBL] [Abstract][Full Text] [Related]
30. Different receptors mediating the inhibitory action of exogenous ATP and endogenously released purines on guinea-pig intestinal peristalsis.
Heinemann A; Shahbazian A; Barthó L; Holzer P
Br J Pharmacol; 1999 Sep; 128(2):313-20. PubMed ID: 10510440
[TBL] [Abstract][Full Text] [Related]
31. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
32. Presence of nicotinic, purinergic and dopaminergic receptors and the TASK-1 K+-channel in the mouse carotid body.
Kåhlin J; Eriksson LI; Ebberyd A; Fagerlund MJ
Respir Physiol Neurobiol; 2010 Jul; 172(3):122-8. PubMed ID: 20452469
[TBL] [Abstract][Full Text] [Related]
33. Merck stakes out 'irritable' neuron territory with $1.25 billion.
Sheridan C
Nat Biotechnol; 2016 Sep; 34(9):900. PubMed ID: 27606448
[No Abstract] [Full Text] [Related]
34. Realism in drug discovery-could Cassandra be right?
Horrobin DF
Nat Biotechnol; 2001 Dec; 19(12):1099-100. PubMed ID: 11731767
[No Abstract] [Full Text] [Related]
35. Industry shifts focus to immunology and cancer.
Ledford H
Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
[No Abstract] [Full Text] [Related]
36. Merck &Co. drops osteoporosis drug odanacatib.
Mullard A
Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681784
[No Abstract] [Full Text] [Related]
37. Deal watch: Harnessing creative risk sharing.
Papp T
Nat Rev Drug Discov; 2010 Sep; 9(9):671. PubMed ID: 20811371
[No Abstract] [Full Text] [Related]
38. When the party's over.
Wadman M
Nature; 2007 Jan; 445(7123):13. PubMed ID: 17203035
[No Abstract] [Full Text] [Related]
39. Merck opts for shake-up to clear drug pipeline.
Nature; 2005 Dec; 438(7071):1076-7. PubMed ID: 16371975
[No Abstract] [Full Text] [Related]
40. Cholinergic and purinergic responses in isolated human detrusor in relation to age.
Wuest M; Morgenstern K; Graf EM; Braeter M; Hakenberg OW; Wirth MP; Ravens U
J Urol; 2005 Jun; 173(6):2182-9. PubMed ID: 15879884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
